TRACON Pharmaceuticals Announces Clinical Data Presentations at Upcoming Medical Meetings

SAN DIEGO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced presentations for TRC105 at the following upcoming medical meetings.

Oral Presentation at Connective Tissue Oncology Society (CTOS) 2015 Annual Meeting
Title: A Phase 1B Dose-Escalation Study of TRC105 (anti-Endoglin Antibody) in Combination with Pazopanib in Patients with Advanced Soft Tissue Sarcoma (STS)
Session Title: Sarcoma of the Year: Angiosarcoma & Hemangioendothelioma
Presenter: Steven Attia, D.O., Mayo Clinic-Jacksonville
Location: The Grand America Hotel, Salt Lake City, UT, Grand Ballroom B&C
Date/Time: Thursday, November 5, 2015, 1:30 PM – 3:00 PM, Mountain time
Poster Presentations at Kidney Cancer Association (KCA) 14th International Kidney Cancer Symposium
Title: A Phase 1B Dose-Escalation Study of TRC105 (anti-Endoglin Antibody) in Combination with Axitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Presenter: Toni Choueiri, M.D., Dana-Farber Cancer Institute
Location: Miami Marriott Biscayne Bay, Miami, FL
Date: Friday, November 6, 2015 – Saturday, November 7, 2015
Title: TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 versus AXitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC)
Presenter: Toni Choueiri, M.D., Dana-Farber Cancer Institute
Location: Miami Marriott Biscayne Bay, Miami, FL
Date: Friday, November 6, 2015 – Saturday, November 7, 2015


About TRC105

TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by both TRACON and the National Cancer Institute for the treatment of multiple solid tumor types in combination with VEGF inhibitors. TRC105 is also being developed in combination with VEGF inhibitor treatments in wet AMD. For more information about the clinical trials, please visit TRACON’s website at http://www.traconpharma.com/clinical_trials.php.

About TRACON

TRACON develops targeted therapies for cancer, wet AMD and fibrotic diseases. TRACON’s pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.


Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 clogan@traconpharma.com Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com

Source:TRACON Pharmaceuticals, Inc.